Skip to main content

Infection

Protective Effects of Colchicine in Non-Hospitalized COVID-19

Jan 25, 2021

A press release from Montreal Heart Institute announced that the COLCORONA clinical trial provided evidence of the protective effect of colchicine; demonstrating a 21% reduced risk of death or hospitalizations in patients with COVID-19 compared to placebo. COLCORONA trial was a contact-less,

Read Article
Low Risk of TB with Secukinumab https://t.co/ADdtMNxy2N https://t.co/YTY0eci5Y2
Dr. John Cush RheumNow ( View Tweet)
Jan 23, 2021

RheumNow Podcast – Don’t Hold the Benlysta, Take the Vaccine (1.22.2021)

Jan 22, 2021

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, with more than a dozen items to discuss on this week's podcast.

Read Article

NEJM: Early Combo Monoclonal Antibody Therapy in COVID-19

Jan 21, 2021

NEJM has published the interim analysis of the REGN-COV2 trial, wherein an antibody cocktail reduced viral loads with less clinical consequences. 



Recent data suggest that high viral loads are associated with greater risk for COVID-19 complications and death. A combination of two

Read Article

Combo Anti-Spike Protein Antibody for Mild to Moderate COVID-19

Jan 21, 2021

JAMA has published the BLAZE-1 study, showing significant SARS-CoV-2 viral load reduction at day 11 and less COVID-19 progression when combination anti-spike monoclonal antibody therapy (bamlanivimab and etesevimab) was given to mild to moderate, non-hospitalized COVID-19 patients.

Read Article

Low Risk of TB with Secukinumab

Jan 20, 2021

JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were found. 

Read Article

Inequities in Telemedicine During COVID-19

MedPage Today
Jan 19, 2021

Health equity in the telehealth age has assumed added importance since the COVID-19 pandemic began. The Federal Communications Commission estimates that about 21 million Americans don't have access to the Internet in their homes. Other sources estimate it is closer to 162 million. However,

Read Article
Pooled analysis of 16 RCTs in 7044 abatacept treated pts (21,274 PYs exposure) found very low risk of opportunistic infections ranging from OIs 0.17 to 0.21 on ABA and 0.56 on placebo - only 13 TB cases; IR for H zoster was low 1.53/100PY https://t.co/kOWYxEmQLd

Dr. John Cush RheumNow ( View Tweet)

Jan 19, 2021

Travel During COVID-19 Pandemic

Jan 18, 2021

The CDC has addressed the effects and the issues of domestic and international travel on its website.  Below is a sampling of key advice.

Read Article

2020 Rheumatology Year in Review

Jan 14, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article

RheumNow Podcast – Lights, Camera, Zoom (1.8.2021)

Jan 08, 2021

Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.

Read Article
Rifampin is safest! 2 RCTs of 6485 latent TB pts compared 9 mos of isoniazid vs 4 mos of rifampicin. RIF had half the adverse events compared to INH; roughly half the rate of rash (1.5% v 2.7%); No grade 3-4 hepatotoxicity w/ RIF, compared 6%) w/ INH https://t.co/6Nz0zeP8ik

Dr. John Cush RheumNow ( View Tweet)

Jan 05, 2021

COVID-19 Vaccination - Phase Ib Begins

Jan 04, 2021

The U.S. Centers for Disease Control and Prevention (CDC) has issued a timeline guidance document on when, how and who should get the commercially available COVID-19 vaccines. 

Read Article

Plaquenil Does Not Protect Lupus Patients from COVID-19 (Best of 2020)

Dec 31, 2020

Annals of Rheumatic Disease reports on an analysis of lupus (SLE) patients that shows COVID-19 infection rates were similar between those lupus patients who were taking hydroxychloroquine (HCQ) and those not taking HCQ. 

Read Article

Best of 2020: The COVID-19 Global Rheumatology Registry

Dec 24, 2020

What started out as online tweets and sharing newsfeed and case reports, has progressed to the formation of the COVID-19 Global Rheumatology Alliance, whose mission is to create an international rheumatology registry of patients affected by the disease in order to better understand the disease

Read Article

Best of 2020: Rheumatic Disease Drugs and COVID-19

Dec 22, 2020

We are in the early stages of trying to limit the morbid and mortal consequences of the corona virus pandemic of 2020. Not surprisingly, the recommendations designed to limit exposure and damage continually highlight the fact that the elderly and immunosuppressed may be amongst the most

Read Article

Best of 2020: The Nine Lives of Hydroxychloroquine (Updated)

Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory

Read Article

ACIP Recommendations for Pfizer-BioNTech COVID-19 Vaccine Use (including Special Populations)

CDC/MMWR
Dec 18, 2020

Following the FDA issuance of an Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine, the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for the prevention of COVID-19 in persons aged ≥16 years. 



The PfizerCOVID-19 vaccine (BNT162b2

Read Article

COVID-19 as a Leading Cause of Death in the USA

Dec 17, 2020

The exponential rise in deaths from the coronavirus (COVID-19) in the last several months is put into perspective by JAMA Viewpoint article noting that current US death rates of > 3000 per day from COVID-19 is greater than that seen in one day on September 11, 2001 (9/11 attacks, claimed 2988

Read Article

RheumNow Podcast – Stop These COVID Mistakes (12.11.20)

Dec 11, 2020

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article

New Lyme Disease Guidelines

Dec 10, 2020

2020 evidence-based clinical practice guideline for the prevention, diagnosis, and treatment of Lyme disease was cooperatively developed the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR). The guideline

Read Article

Rheumatic Disease and COVID-19: Who Is at Risk?

MedPage Today
Dec 10, 2020

Patients with rheumatic and inflammatory diseases who develop COVID-19 share risk factors for severe disease with the larger population, including older age, male sex, obesity, and hypertension, but also are at increased risk if they are on corticosteroids, French investigators reported.

Read Article
Dr. Mrinalini Dey ( @DrMiniDey) interviews Dr. James Galloway on infection in rheumatic diseases, and the studies and presentations he's interested in on infection at #ACR20. https://t.co/5HE7ByhjXo https://t.co/77oLtO2MEQ
Dr. John Cush RheumNow ( View Tweet)
Nov 27, 2020

RheumNow Podcast – ACR 2020 Epilogue (11.20.20)

Nov 20, 2020

Dr. Jack Cush reviews a few more ACR 2020 abstracts and presents a new plan to learn or take in ACR20 content.

Read Article
Read our recap on Tofacitinib for Ankylosing Spondylitis by Sheila Marie Reyes ( @RHEUMarampa) #ACR20 https://t.co/E9zJXuq1u4 https://t.co/nmBRnkwOif
Dr. John Cush RheumNow ( View Tweet)
Nov 14, 2020
×